Skip to content
Disclosery

ARCH Venture Management, LLC

Follow

13F filer, CIK 1274403, CHICAGO, IL

ARCH Venture Management, LLC reported $206,219,148 across 9 holdings for the quarter ended 2025-03-31, in a 13F-HR filed 2025-05-15.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001012975-25-000245

Period
2025-03-31
Reported value
$206M
Holdings
9
Top 10 weight
100%
New
2
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
MAZEnew+4,120,053$45.4M
CERO THERAPEUTICS HLDGS INCnew+22,102$16.1K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
SINGULAR GENOMICS SYSTEMS INexited-126,630-$2.46M
CERO THERAPEUTICS HLDGS INCexited-9,393,561-$564K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2025

Share positions as resolved from 13F-HR 0001012975-25-000245, largest first. % of portfolio is the value over $206,219,148, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BEAMBEAM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,834,653 shares; 2024Q4: 4,540,132 shares; 2025Q1: 4,540,132 shares 4,540,132$88.7M43%0Timeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 4,120,053 shares 4,120,053$45.4M22%newTimeline
RAPPRAPPORT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,728,738 shares; 2024Q4: 3,728,738 shares; 2025Q1: 3,728,738 shares 3,728,738$37.5M18.21%0Timeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 11,055,554 shares; 2024Q4: 11,055,554 shares; 2025Q1: 11,055,554 shares 11,055,554$15.1M7.34%0Timeline
VERVE THERAPEUTICS INCVERVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,008,809 shares; 2024Q4: 2,008,809 shares; 2025Q1: 2,008,809 shares 2,008,809$9.12M4.42%0
GOSSGOSSAMER BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 8,055,916 shares; 2024Q4: 8,055,916 shares; 2025Q1: 8,055,916 shares 8,055,916$8.78M4.26%0Timeline
UNITY BIOTECHNOLOGY INC COM…UNITY BIOTECHNOLOGY INC COM NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,004,817 shares; 2024Q4: 1,004,817 shares; 2025Q1: 1,004,817 shares 1,004,817$1.05M0.51%0
QTTBQ32 BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 320,482 shares; 2024Q4: 320,482 shares; 2025Q1: 320,482 shares 320,482$532K0.26%0Timeline
CERO THERAPEUTICS HLDGS INCCERO THERAPEUTICS HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 22,102 shares 22,102$16.1K0.01%new

Sold out in Q1 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
SINGULAR GENOMICS SYSTEMS INSINGULAR GENOMICS SYSTEMS IN126,630$2.46Mshares
CERO THERAPEUTICS HLDGS INCCERO THERAPEUTICS HLDGS INC9,393,561$564Kshares

How Q1 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001012975-25-000245 base2025-05-15acceptance time not in the bulk data set